☆ 4.5 Letter

In response to who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies

RESPIRATORY MEDICINE (2022)

Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies

Maya Desai et al.

Summary: Patients from black, Asian and minority ethnic backgrounds are significantly less likely to be eligible for ivacaftor/tezacaftor/elexacaftor based on the current prescribing policy in the UK. These findings highlight the need for effective targeted therapies for cystic fibrosis patients without the F508del mutation.

RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Pediatrics

Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype

Meghan E. McGarry et al.

Summary: This study found that minority groups of cystic fibrosis patients are less likely to be eligible for CFTR modulator therapy, potentially leading to increased disease severity and earlier mortality. This will further contribute to health disparities among people with cystic fibrosis.

PEDIATRIC PULMONOLOGY (2021)

添加到收藏夹

Article Pediatrics